Population
Patients with end-stage renal disease (ESRD)
Design
Review
Authors
Loading...
Alerts clinicians to non-atheromatous remodeling in dialysis CV mortality; leaves open targeted therapies beyond plaque stabilization.
Cardiovascular disease in ESRD is driven not only by accelerated atherosclerosis but also by significant non-atheromatous arterial remodeling and stiffening, which alters hemodynamics and increases left ventricular afterload.
London et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: